- Challenging market conditions for ethical drugs in Japan (governmental promotion of generic drug usage and new drug patent cliff)
- Decreased sales due to annual NHI drug price revisions
- Instability of pharmaceuticals supply
- Rising prices due to a weaker yen
- Increasing complexity of new drug development
- Increasingly diverse drug discovery modalities
- Competition with rival products (including generics)
- Climate change risks (physical and transition risks)
Mochida Pharmaceutical Group (Mochida Pharmaceutical Co., Ltd. and its consolidated subsidiaries)
Greenhouse gas emissions & sustainability report data
In its 2023-04 to 2024-03 reporting, Mochida Pharmaceutical Group (Mochida Pharmaceutical Co., Ltd. and its consolidated subsidiaries) disclosed greenhouse gas emissions of 15.1K t-CO2e/year (FY2023). By scope: Scope 1: 4.3K t-CO2e/year (FY2023); Scope 2: 10.4K t-CO2e/year (FY2023). Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.
GHG Emissions
15.1K t-CO2e/year (FY2023)
2023-04 to 2024-03
Water Usage
306.0K m3/year (FY2023)
2023-04 to 2024-03
Waste
533 tons/year (FY2023)
2023-04 to 2024-03
Energy Use
347 TJ/year (FY2023)
2023-04 to 2024-03
📊 Emissions by Scope (2023-04 to 2024-03)
| Scope | What it covers | Reported value |
|---|---|---|
| Scope 1 | Direct emissions from sources the company owns or controls (fuel combustion, company vehicles, process and fugitive emissions). | 4.3K t-CO2e/year (FY2023) |
| Scope 2 | Indirect emissions from purchased electricity, steam, heat and cooling. | 10.4K t-CO2e/year (FY2023) |
New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.
✅ Reported Environmental Achievements
- Reduced CO2 emissions by 15.4% from FY2013 levels by FY2023
- Headquarters building received a top-level BELS 5-star rating and was certified as “ZEB Ready”
- Replaced below-ground drainage system with an above-ground system at Head Office Plant to prevent soil contamination
🎯 Climate & Sustainability Targets
📅 Medium-term
- Reduce carbon emissions by 46% from FY2013 levels by FY2030
- Reduce waste to 582 tons or lower by FY2030
- Increase waste recycling rate to 98% or higher by FY2030
- Maintain a plastic waste recycling rate of 65% or higher by FY2030
- Target ratio of female managers of 12% or higher (FY2021-FY2025)
🔭 Long-term
- Reach carbon neutrality by 2050
- Total net sales of 140 billion yen and an operating margin of 15% by 2031
🌱 ESG Focus Areas
Human resource developmentComplianceCreation of unique products to meet needsStable supply of high-quality pharmaceuticalsProper provision of valuable informationClimate changeHuman rightsWomen's health